References
  1. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870.
  2. Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome–a case review. Hum Psychopharmacol. 2003;18(4):301.
  3. Desai D, Gupta K, Kumar R, Biswas A. Levosulpiride-induced neuroleptic malignant syndrome in rheumatoid arthritis. BMJ Case Rep. 2018;2018 Epub 2018 Aug 11.
  4. Velamoor VR. Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Saf. 1998;19(1):73.
  5. Velamoor VR, Norman RM, Caroff SN, Mann SC, Sullivan KA, Antelo RE. Progression of symptoms in neuroleptic malignant syndrome. J NervMent Dis. 1994;182(3):168.
  6. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142(10):1137.
  7. Picard LS, Lindsay S, Strawn JR, Kaneria RM, Patel NC, Keck PE Jr. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy. 2008;28(4):530.
  8. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1):185.
  9. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry. 1989;50(1):18.
  10. Young Kyoung Sa et al. Olanzapine-Induced Diabetic Ketoacidosis and Neuroleptic Malignant Syndrome with Rhabdomyolysis: A Case Report. Endocrinol Metab 2013; 28:70-75.
  11. Pileggi DJ, Cook AM. Neuroleptic Malignant Syndrome. Ann Pharmacother. 2016;50(11):973. Epub 2016 Jul 19.
  12. Ann Pharmacother. 2016;50(11):973. Epub 2016 Jul 19. Recurrent sinus arrest in association with neuroleptic malignant syndrome. Br J Psychiatry. 1994;164(5):689.
  13. GuzéBH, Baxter LR Jr. Current concepts. Neuroleptic malignant syndrome. N Engl J Med. 1985;313(3):163.
  14. Lappa A, PodestàM, Capelli O, Castagna A, Di Placido G, Alampi D, Semeraro F. Successful treatment of a complicated case of neuroleptic malignant syndrome. Intensive Care Med. 2002;28(7):976. Epub 2002 Jun 7.
  15. Morgan C,Rowe R. The prevalence of neuroleptic malignant syndrome in learning disability. Irish Journal of Psychological Medicine 2003.
  16. SheehanR,HorsfallL,StrydomA,OsbornD,Walters K,Hassiotis A. Movement side effects of antipsychoticdrugs in adults with and withoutintellectual disability: UK populationbasedcohort study. BMJ Open 2017;7:e017406.
  17. Kaufman K, Levitt MJ, Shiltz JF, Sunderram J. Neuroleptic Malignant Syndrome and Serotonin Syndrome in the Critical Care Setting: Case Analysis. Annals of Clinical Psychiatry, 18[3]:201–204, 2006
  18. HernándezJL,RamosF,InfanteJ,Rebollo M, González-Macías J. Severe Serotonin Syndrome Induced by Mirtazapine Monotherapy. The Annals of Pharmacotherapy. 2002 April, Volume 36
  19. SchattnerA,KitroserE,Cohen JD.Fatal Neuroleptic Malignant Syndrome Associated With Quetiapine.American Journal of Therapeutics 0, 1–2 (2015).
  20. O’Dwyer AM and Sheppard N. The role of creatine kinase in the diagnosis of Neuroleptic Malignant Syndrome. Psychological Medicine, 1993, 23, 323-326.
  21. BNF – British National Formulary 79 March - September 2020.